Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
154 hedge funds and large institutions have $2.61B invested in Aegerion Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 60 increasing their positions, 58 reducing their positions, and 20 closing their positions.
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
34% more capital invested
Capital invested by funds: $1.95B → $2.61B (+$661M)
24% more call options, than puts
Call options by funds: $204M | Put options by funds: $165M
6% more funds holding
Funds holding: 145 → 154 (+9)
3% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 58
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$60.1M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$53.8M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$40.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.9M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$38.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$106M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$70M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$69.1M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$28.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$20M |
AEGR Hedge Fund Activity: Q3 2013 in Review
154 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q3 2013, worth a combined $2.61B — up 34% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new AEGR positions and 20 closed out — a net gain of 11 holders — while 60 added to existing stakes and 58 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $60.1M. The largest seller was Perceptive Advisors, cutting an estimated $106M.
- 154 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q3 2013, up from 145 in Q2 2013.
- Funds reported $2.61B of Aegerion Pharmaceuticals stock for Q3 2013, up 34% quarter-over-quarter.
- 31 funds opened new Aegerion Pharmaceuticals positions in Q3 2013 and 20 closed out, a net change of +11 holders.
- The largest Aegerion Pharmaceuticals buyer in Q3 2013 was Viking Global Investors, an estimated $60.1M added.
- The largest Aegerion Pharmaceuticals seller in Q3 2013 was Perceptive Advisors, an estimated $106M sold.
Based on aggregated 13F filings for Q3 2013.